Essential Pharmaceuticals releases new data on bioproduction scalability using Cell-Ess media supplement
EWING, N.J., Jan. 13, 2016 /PRNewswire/ — Essential Pharmaceuticals, LLC releases new data on bioproduction scalability using Cell-Ess® media supplement. Cell-Ess, a chemically-defined and animal component free supplement, delivers critical components needed for cell growth. Cell-Ess can be used as a building block to create robust media to address the cell culture demands of bioproduction. Scalable protein biomanufacturing was boosted by the addition of this novel supplement to a previously optimized CHO serum-free media.
Addition of Cell-Ess results in a significant increase in productivity. “Cell-Ess used as an initial supplement or as a feed resulted in greater than 25% increases in two independent monoclonal antibody clones,” says Dr. Adam Elhofy, CSO of Essential Pharmaceuticals. “The increase in protein production was observed in both raw titer and on a per cell basis.”
Scalability is a problem faced across many platforms in manufacturing. In a previous data release, Cell-Ess demonstrated the ability to increase monoclonal antibody productivity and titer. New data to be released demonstrates that the benefits of Cell-Ess are scalable. Cell-Ess was used as a feed at 5% (v/v) in a small Wave bioreactor resulting in greater than 25% monoclonal antibody titer increase, which was similar to the gains seen in earlier experiments using shake flasks. Small bioreactors have been used as models to show scalability to up to 10,000-liter manufacturing runs. These new data suggest supplementing with Cell-Ess as a feed will result in increased monoclonal antibody titers for 10,000-liter bioreactor runs.
Essential Pharmaceuticals is currently evaluating the effects of Cell-Ess on other important aspects of bioprocessing, including use in single-use bioreactors (SUBs), protein quality and cell metabolism.
“At Essential Pharmaceuticals, we provide solutions to manage organs, tissues and individual cells for research purposes,” says Allan Weber, CEO. “We are very excited to see how this new application of Cell-Ess will enable bioproduction scientists to produce better engineered proteins for therapeutic use in a chemically-defined manner.”
About Essential Pharmaceuticals
Essential Pharmaceuticals provides transplant surgeons, medical researchers, and manufacturers new tools to bring performance, convenience, and control to enhance the advancement of basic research and drug discovery. Established in 2006, Essential Pharmaceuticals supports the preservation and growth of human systems through expanding its product development to further medical treatments for mankind.
Denise A. Weber
Princeton South Corporate Center
Ewing, NJ 08628